CVS is opting against covering a twice-yearly injectable HIV prevention drug, drawing criticism from advocates who are ...

CVS Health, one of the nation’s largest pharmacy benefit managers, has declined to cover Gilead’s newly FDA-approved HIV ...

At the International AIDS Society meeting this year, a young woman from South Africa spoke. She is the first Black woman from ...

The absolute and relative HIV-attributable cancer burden varies globally. These data can inform region-specific planning and evaluation of HIV control, as well as cancer-specific interventions such as ...

Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

E xecutives at Gilead Sciences, the biotech behind a long list of HIV treatments and preventative medicines, have spoken with ...